Exchange: NASDAQ·Updated 07:59 PM EDT
BCAB logo

BCAB BioAtla Inc

$1.74
$1.41
(44.74%)
Today
Closed $1.74
$0.025
(1.44%)
After Hours
EarningsNov 12
Mkt Cap$2.89M
Vol1.03M

About BCAB

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
39

Bearish Sentiment

How do you feel about BCAB?

Advertisement|Remove ads.